Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas

被引：0
|
作者：
Dacic, S.
Poppei, H. H.
Kothmaier, H.
Halbwedt, I.
Morbini, P.
Murer, B.
Comin, C. E.
Galateau-Salle, F.
Demirag, F.
Zeren, H.
Allanoos, R.
Gibbs, A.
Cagle, P. T.
机构：
[1] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[2] Inst Pathol, Graz, Austria
[3] Inst Pathol Anat, Pavia, Italy
[4] Osped Umberto 1, Venice, Italy
[5] Univ Florence, I-50121 Florence, Italy
[6] CHU Cote Nacre, Caen, France
[7] Ataturk Chest Dis Hosp, Ankara, Turkey
[8] Adana Univ, Adana, Turkey
[9] Llandough Hosp, Cardiff & Vale NHS Trust, Cardiff, Wales
[10] Methodist Hosp, Houston, TX USA
来源：
MODERN PATHOLOGY | 2008年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1547
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [41] Comparing p16 and MTAP loss of expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
    Vizcaino, M. A.
    Mendoza, C. Zepeda
    Vaubel, R.
    Nguyen, A. T.
    Trejo-Lopez, J. A.
    Raghunathan, A.
    Jenkins, S.
    Jenkins, R.
    Giannini, C.
    BRAIN PATHOLOGY, 2023, 33
  • [42] Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-Leiden)
    Cappel, WHDTN
    Offerhaus, GJA
    van Puijenbroek, M
    Caspers, E
    Gruis, NA
    de Snoo, FA
    Lamers, CBHW
    Griffioen, G
    Bergman, W
    Vasen, HFA
    Morreau, H
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3598 - 3605
  • [43] p16/CDKN2A deletion as a diagnostic marker to distinguish benign from malignant mesothelial proliferations
    Chung, C. T-S
    Santos, G. C.
    Hwang, D. M.
    Ludkovski, O.
    Squire, J.
    Tsao, M-S
    LABORATORY INVESTIGATION, 2008, 88 : 338A - 338A
  • [44] Investigating the Use of p16 Immunohistochemistry as a Surrogate Marker for CDKN2A/B Homozygous Deletion in Astrocytomas
    Cho, Benjamin
    Umphlett, Melissa
    Tsankova, Nadejda
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2021, 80 (06): : 572 - 573
  • [45] p16/CDKN2A deletion as a diagnostic marker to distinguish benign from malignant mesothelial proliferations
    Chung, C. T-S
    Samos, G. C.
    Hwang, D. M.
    Ludkovski, O.
    Squire, J.
    Tsao, M-S
    MODERN PATHOLOGY, 2008, 21 : 338A - 338A
  • [46] EVALUATION OF P16 AND MTAP IMMUNOHISTOCHEMICAL EXPRESSION AS SURROGATE MARKERS OF CDKN2A/B DELETION IN MENINGIOMAS
    Ricci, A. A.
    Tampieri, C.
    Nozzoli, F.
    Buccoliero, A. M.
    Mangherini, L.
    di Cantogno, L. Verdun
    Osella-Abate, S.
    Pellerino, A.
    Bruno, F.
    Ruda, R.
    Garbossa, D.
    Massi, D.
    Cassoni, P.
    Bertero, L.
    NEURO-ONCOLOGY, 2023, 25 : 123 - 123
  • [47] Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
    Vizcaino, M. Adelita
    Giannini, Caterina
    Vaubel, Rachael A.
    Nguyen, Aivi T.
    Trejo-Lopez, Jorge A.
    Raghunathan, Aditya
    Jenkins, Sarah M.
    Jenkins, Robert B.
    Mendoza, Cinthya J. Zepeda
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (12): : 1003 - 1009
  • [48] Uterine Inflammatory Myofibroblastic Tumors: p16 as a Surrogate for CDKN2A Deletion and Predictor of Aggressive Behavior
    Devins, Kyle M.
    Ordulu, Zehra
    Mendoza, Rachelle P.
    Croce, Sabrina
    Haridas, Rishikesh
    Wanjari, Pankhuri
    Pinto, Andre
    Oliva, Esther
    Bennett, Jennifer A.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (07) : 813 - 824
  • [49] P16/CDKN2A deletion as a diagnostic marker to distinguish benign from malignant mesothelial proliferations
    Chung, Catherine
    Hwang, David
    Tsao, Ming-sound
    MODERN PATHOLOGY, 2006, 19 : 164 - 165
  • [50] Prognostic impact of CDKN2A deletion in oligodendroglioma
    Smith, V.
    Stevenson, K.
    Wieden, T.
    Anand, M.
    Desjardins, A.
    McLendon, R.
    Ashley, D.
    Gregory, S.
    Lopez, G.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2024, 83 (06): : 441 - 442
12345